AbbVie Inc. stock gains on Apogee deal and blood cancer trial progress

AbbVie Inc. stock is trading near its 52-week high as investors weigh a USD 10.9 billion Apogee Therapeutics acquisition and promising late-stage data for a blood cancer therapy alongside a solid dividend profile and consensus buy ratings.

AbbVie Inc. stock (ISIN US00287Y1091) is trading close to its 52-week high after the biopharmaceutical group completed a USD 10.9 billion acquisition of Apogee Therapeutics and reported encouraging late-stage data for a blood cancer therapy on September 3, 2026, according to recent market and company updates.

Apogee acquisition reshapes AbbVie’s immunology pipeline

On September 3, 2026, AbbVie announced that it had completed the acquisition of Apogee Therapeutics in a transaction valued at approximately USD 10.9 billion, strengthening its portfolio in dermatology and respiratory diseases, according to an overview of the deal reported by GuruFocus.

The same analysis notes that AbbVie’s stock price stood at USD 261.72 as of the latest close, which is around 19.1% above the service’s calculated GF Value of USD 219.78, suggesting the shares are trading at a premium to that intrinsic value metric while investors price in the Apogee pipeline and AbbVie’s established cash generation. In the 52-week period, AbbVie has traded between USD 190.75 and USD 267.47, with the recent closing price of USD 261.72 placing the stock near the upper end of that range, according to market data cited by RTTNews.

Blood cancer trial meets late-stage goals

In parallel to the Apogee deal, AbbVie highlighted progress in oncology: the company reported that its therapy for a type of blood cancer lowered the risk of disease progression or death and improved the response rate to treatment in a late-stage trial, meeting the study’s primary goals, according to a summary of the Phase 3 CERVINO trial published on September 3, 2026 by WHBL.

Further detail on the same Phase 3 CERVINO study indicates that etentamig, a bispecific T-cell engager for triple-class exposed relapsed or refractory multiple myeloma, achieved dual primary endpoints and produced promising topline results, reinforcing AbbVie’s strategy to offset biosimilar pressure on legacy products with newer oncology assets, as outlined by GuruFocus on September 3, 2026.

Dividend, valuation and analyst view

Dividend strength remains a central part of the AbbVie investment case: one valuation note from September 3, 2026 points out that AbbVie’s dividend yield sits well above the broader large-cap healthcare peer group, with the company classified as a reliable payer even as the shares are judged to be around 18.1% to 19.1% above estimated intrinsic value depending on the exact price snapshot used, according to an assessment of AbbVie’s GF Value and payout profile by GuruFocus.

On the sell-side, consensus data compiled by MarketBeat on September 3, 2026 show that AbbVie shares carry a “Moderate Buy” rating with an average target price of USD 275.95, implying modest upside from the current USD 261.50 to USD 261.72 trading zone and reflecting confidence that execution on acquisitions such as Apogee and trial programs like etentamig can sustain earnings growth, as seen in recent alerts about institutional buying reported by MarketBeat.

Representative product: SKYRIZI in immunology

A key commercial product underpinning AbbVie’s immunology franchise and its ability to finance pipeline investments is SKYRIZI (risankizumab-rzaa), which the company continues to develop for additional indications beyond plaque psoriasis, including psoriatic arthritis; as of August 27, 2026, AbbVie reported a regulatory application submission update for SKYRIZI in psoriatic arthritis, illustrating how established brands help support revenue while newer assets from Apogee and the oncology pipeline move through trials, according to an events overview compiled by MarketBeat.

AbbVie Inc. stock near its recent high

From a market perspective, AbbVie Inc. stock is listed on the New York Stock Exchange under the ticker ABBV and most recently opened at USD 261.50 on September 3, 2026, with a one-year trading range between USD 190.75 and USD 267.47, according to data shared in several institutional activity updates from MarketBeat.

AbbVie Inc. stock facts

• Company: AbbVie Inc.
• ISIN: US00287Y1091
• Ticker: ABBV
• Trading venue: NYSE
• Price (as of September 3, 2026): 261.50 USD
• Market capitalization: [value] USD (as of September 3, 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500